Supernus Pharma sinks after depression drug fails mid-stage trial goal

Supernus Pharmaceuticals

19/02/2025 11:15

** Shares of drugmaker Supernus Pharmaceuticals  SUPN.O 
fall ~22% to $31 premarket
    ** On late Tuesday, co said its depression drug, SPN-820,
did not meet main goal of reduction in depressive symptoms in a
mid-stage trial
    ** Trial tested 250 patients with treatment-resistant
depression and found no statistically significant change
compared to a placebo
    ** Trial used Montgomery-Asberg Depression Rating Scale to
measure severity of depression symptoms such as sadness, inner
tension, sleep reduction and inability to feel
    ** SUPN gained 30.4% in 2024
 

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))